MML Investors Services
NBIX icon

MML Investors Services’s Neurocrine Biosciences NBIX Stock Holding History

MML Investors Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Buy
13,856
+5,705
+70% +$846K ﹤0.01% 1440
2026
Q1 		$1.07M Sell
8,151
-3,579
-31% -$475K ﹤0.01% 1727
2025
Q4 		$1.66M Sell
11,730
-1,289
-10% -$187K ﹤0.01% 1476
2025
Q3 		$1.83M Buy
13,019
+999
+8% +$135K ﹤0.01% 1371
2025
Q2 		$1.51M Buy
12,020
+1,090
+10% +$125K ﹤0.01% 1423
2025
Q1 		$1.21M Sell
10,930
-462
-4% -$58.5K ﹤0.01% 1460
2024
Q4 		$1.55M Buy
11,392
+1,559
+16% +$193K 0.01% 1258
2024
Q3 		$1.13M Sell
9,833
-129
-1% -$17.7K ﹤0.01% 1394
2024
Q2 		$1.37M Sell
9,962
-74
-0.7% -$10.1K 0.01% 1233
2024
Q1 		$1.38M Buy
10,036
+2,756
+38% +$376K 0.01% 1240
2023
Q4 		$959K Buy
7,280
+1,215
+20% +$140K ﹤0.01% 1396
2023
Q3 		$682K Buy
6,065
+107
+2% +$11.3K ﹤0.01% 1453
2023
Q2 		$562K Sell
5,958
-954
-14% -$93.2K ﹤0.01% 1566
2023
Q1 		$700K Sell
6,912
-1,392
-17% -$145K ﹤0.01% 1242
2022
Q4 		$992K Buy
8,304
+1,212
+17% +$142K 0.01% 1153
2022
Q3 		$753K Buy
7,092
+123
+2% +$12.5K 0.01% 1211
2022
Q2 		$679K Buy
6,969
+319
+5% +$29.4K 0.01% 1248
2022
Q1 		$623K Buy
6,650
+1,944
+41% +$165K ﹤0.01% 1339
2021
Q4 		$401K Sell
4,706
-3,752
-44% -$345K ﹤0.01% 1534
2021
Q3 		$811K Sell
8,458
-136
-2% -$12.8K 0.01% 1117
2021
Q2 		$836K Buy
8,594
+1,918
+29% +$184K 0.01% 1077
2021
Q1 		$649K Buy
6,676
+205
+3% +$21.5K 0.01% 1131
2020
Q4 		$620K Sell
6,471
-1,578
-20% -$152K 0.01% 1049
2020
Q3 		$774K Buy
8,049
+4,873
+153% +$564K 0.01% 869
2020
Q2 		$387K Buy
+3,176
New +$351K 0.01% 1116
2020
Q1 		– Sell
-1,953
Closed -$210K – 1496
2019
Q4 		$210K Buy
+1,953
New +$204K ﹤0.01% 1411

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

MML Investors Services's NBIX Position: Q2 2026 in Review

MML Investors Services increased its Neurocrine Biosciences (NBIX) stake by 70% in Q2 2026, buying an estimated $846K and bringing the position to 13,856 shares worth $2.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1440.

MML Investors Services first reported a position in NBIX in Q4 2019 and has held it in 26 quarters since. 427 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • MML Investors Services held 13,856 shares of Neurocrine Biosciences worth $2.34M as of Q2 2026.
  • MML Investors Services bought 5,705 Neurocrine Biosciences shares in Q2 2026, an estimated $846K.
  • Neurocrine Biosciences made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #1440 holding.
  • MML Investors Services first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 26 quarters since.
  • 427 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.